Table 4 The changes in the uptake rate of Mitoxantrone in 482 R, 482 G and 482 T BCRP transfected HEK cell line in the presence of substrate compounds
From: Computational analysis and predictive modeling of polymorph descriptors
| Â | Â | Changes in Uptake of Mitoxantrone (cm/sec: %) | ||
|---|---|---|---|---|
| Â | Â | 482R | 482G | 482T |
| Â | Mitoxantrone | 23.71 (100%) | 27.43 (100%) | 25.92 (100%) |
Training Set | Caffeine | 29.64 (125%) | 41.42 (151%) | 46.28 (140%) |
Ciprofloxacin | 57.38 (242%) | 63.91 (233%) | 45.88 (177%) | |
Cyclosporin | 70.18 (296%) | 66.93 (244%) | 63.76 (246%) | |
Diltiazem | 55.95 (236%) | 59.52 (217%) | 32.40 (125%) | |
Erythromycin | 37.93 (160%) | 48.00 (175%) | 50.02 (193%) | |
Estradiol | 29.87 (126%) | 31.27 (114%) | 26.70 (103%) | |
Febendazole | 30.82 (130%) | 34.83 (127%) | 38.36 (148%) | |
Ketoconazole | 64.50 (272%) | 70.22 (256%) | 68.17 (263%) | |
Nifedipine | 38.17 (161%) | 42.52 (155%) | 38.36 (148%) | |
Novobiocin | 56.90 (240%) | 77.35 (282%) | 71.02 (274%) | |
Quinidine | 38.64 (163%) | 41.97 (153%) | 33.17 (128%) | |
Raloxifene | 46.47 (196%) | 55.95 (204%) | 23.58 (91%) | |
Rhodamine 123 | 44.57 (188%) | 33.74 (123%) | 43.02 (166%) | |
Riboflavin | 41.25 (174%) | 35.92 (131%) | 36.80 (142%) | |
Saquinavir | 46.00 (194%) | 57.33 (209%) | 72.83 (281%) | |
Tamoxifene | 31.30 (132%) | 38.67 (141%) | 40.95 (158%) | |
Verapamil | 29.87 (126%) | 58.42 (213%) | 31.36 (121%) | |
Test Set | Acyclovir | 50.26 (212%) | 66.91 (244%) | 68.95 (266%) |
Epinephrine | 42.91 (181%) | 33.73 (123%) | 24.89 (115%) | |
Foscarnet | 29.87 (126%) | 30.45 (111%) | 33.17 (128%) | |
FumitremorginC | 26.76 (305%) | 79.82 (291%) | 84.75 (327%) | |
Ketoconazole | 64.02 (270%) | 70.77 (258%) | 68.17 (263%) | |
PEITC | 68.28 (288%) | 85.85 (313%) | 85.27 (329%) | |
| Â | Quercetin | 58.56 (247%) | 69.12 (252%) | 61.95 (239%) |